S
S. Ramanujam
Researcher at University of Sydney
Publications - 9
Citations - 993
S. Ramanujam is an academic researcher from University of Sydney. The author has contributed to research in topics: Melanoma & Ipilimumab. The author has an hindex of 6, co-authored 8 publications receiving 804 citations.
Papers
More filters
Journal ArticleDOI
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
Alexander M. Menzies,Alexander M. Menzies,Douglas B. Johnson,S. Ramanujam,Victoria Atkinson,Annie Wong,John J. Park,Jennifer L. McQuade,Alexander N. Shoushtari,Katy K. Tsai,Zeynep Eroglu,Oliver Klein,Jessica C. Hassel,Jeffrey A. Sosman,Alexander Guminski,Alexander Guminski,Ryan J. Sullivan,Antoni Ribas,Matteo S. Carlino,Michael A. Davies,Shahneen Sandhu,Georgina V. Long,Georgina V. Long +22 more
TL;DR: The results support that anti-PD-1 can be administered safely and can achieve clinical benefit in patients with preexisting ADs or prior major irAEs with ipilimumab.
Journal ArticleDOI
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
Elizabeth Liniker,Alexander M. Menzies,Benjamin Y. Kong,Adam Cooper,S. Ramanujam,Serigne Lo,Richard F. Kefford,Gerald B Fogarty,Alexander Guminski,Tim Wang,Matteo S. Carlino,Angela Hong,Georgina V. Long +12 more
TL;DR: RT and anti-PD-1 antibodies can be safely combined, with no detectable excess toxicity in extracranial sites, although there are rare toxicities and the role of either anti- PD-1 or WBRT in the etiology of these is uncertain.
Journal ArticleDOI
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
Samantha Bowyer,Prashanth Prithviraj,Paul Lorigan,James Larkin,Grant A. McArthur,Victoria Atkinson,Michael Millward,Michael Millward,M. Khou,Stefan Diem,S. Ramanujam,Benjamin Y. Kong,Elizabeth Liniker,Alexander Guminski,Phillip Parente,Miles C. Andrews,Sagun Parakh,Jonathan Cebon,Georgina V. Long,Matteo S. Carlino,Matteo S. Carlino,Oliver Klein +21 more
TL;DR: Ipilimumab therapy can induce responses in patients who fail the anti-PD-1 therapy with response rates comparable to previous reports, but there appears to be an increased frequency of high-grade immune-related adverse events including pneumonitis that warrants close surveillance.
Journal ArticleDOI
Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy.
Benjamin Y. Kong,Alexander M. Menzies,Catherine A.B. Saunders,Elizabeth Liniker,S. Ramanujam,Alexander Guminski,Richard F. Kefford,Georgina V. Long,Matteo S. Carlino +8 more
TL;DR: Isolated metabolically active lesions in clinically well patients may reveal immune cell infiltrates rather than melanoma, and patients with residual metastases after a prolonged period without progression on anti‐PD‐1 therapy may have metabolically inactive lesions.
Journal ArticleDOI
Systemic therapies for melanoma brain metastases: which drug for whom and when?
TL;DR: This review will examine the evidence for systemic therapies in patients with active melanoma brain metastasis (untreated or treated and progressed) and highlight active and evolving clinical trials in this challenging field.